BridgeBio Pharma (BBIO) Gains from Investment Securities (2021 - 2023)

BridgeBio Pharma has reported Gains from Investment Securities for 3 years, with the latest figure at -$1.0 million in Q4 2023.

• Quarterly Gains from Investment Securities fell 928.8% year-over-year to -$1.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$984000.0 (down 108.74% YoY) and the FY2023 annual result came in at -$984000.0, down 162.64% from the prior year.
• Gains from Investment Securities retreated to -$1.0 million in Q4 2023 per BBIO's latest filing, from $274000.0 in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $10.2 million in Q2 2022 and troughed at -$1.0 million in Q4 2023.
• A 3-year average of $1.0 million and a median of $125000.0 in 2022 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities soared 815.04% in 2022, then plunged 928.8% in 2023.
• Over 3 years, Gains from Investment Securities stood at $738000.0 in 2021, then slumped by 83.06% to $125000.0 in 2022, then slumped by 928.8% to -$1.0 million in 2023.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$1.0 million, $274000.0, and -$111000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.